<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1538973079464292&amp;ev=PageView&amp;noscript=1">

LIAISON LymeDetect®
for EARLY Lyme Disease Detection

Seeking volunteers in New York, New Jersey, and Connecticut for a new Lyme disease diagnostic test



todo_blue Research Study Details


The study is enrolling individuals meeting one of the following conditions:


Step 1
  • Recently diagnosed with early-stage Lyme disease by clinician (must be a new infection)
  • Erythema migrans rash within the last 6 weeks
  • On antibiotics for no more than 7 days
  • Must be able to visit study site for one blood draw
Step 2
  • Diagnosed with early-stage Lyme disease by clinician
  • Individuals without erythema migrans rash
  • Signs and symptoms consistent with Lyme disease (e.g. fever, chills, headache, fatigue, muscle & joint aches, swollen lymph nodes)
  • Known or suspected tick bite within 8 weeks
  • Must be able to visit study site for one blood draw

New York


BCHP - Bradhurst Avenue Specialty Offices
19 Bradhurst Avenue
Hawthorne NY, 10532
*(Only accepting pediatric volunteers ages 5 – 17 years old)

New York


Circuit Clinical/Crystal Run Healthcare LLP
75 Crystal Run Road, Middletown NY, 10941

New Jersey


Plasma Services Group
1503 Glen Avenue, Unit 100
Moorestown, NJ 08057

New Jersey


Circuit Clinical/Riverside Medical Group
38 Meadowlands Pkwy., Ste 205, Seacacus NJ, 07094

 This study shall evaluate the investigational LIAISON LymeDetect® test in the US in comparison to existing methodologies.
LIAISON LymeDetect® is an innovative approach to EARLY Lyme disease diagnostics that combines assays measuring B cell response, LIAISON® IgG and IgM CLIA assays, and T cell response with the patented QuantiFERON® IGRA technology.
Lyme disease is one of the fastest growing infectious diseases worldwide. It is also one of the most difficult to diagnose due to inefficient diagnostic tests. Your participation in this study will help us advance a diagnostic (new lab test) that will significantly improve accuracy and time to diagnosis. Early Lyme disease detection is key for better treatment outcomes.
You will meet with the study team at an enrolling center to review the study details and to confirm your eligibility for participation. If eligible, you will provide a small amount of health information and a one-time blood draw.

One Tick Bite is All it Takes…

Lyme disease (Borreliosis) is the fastest growing vector-borne illness worldwide. It is a bacterial infection that is contracted from being bitten by an infected deer tick. An estimated, 476,000 people contract Lyme disease every year in the United States. Your risk for contracting Lyme disease is steadily increasing each year. It is important we take steps to improve the way we diagnose this illness.
Lyme disease

Lyme disease

Is the fastest growing vector-borne illness worldwide



People contract Lyme disease each year in the United States


Why This Research Study is Important

The CDC currently recommends a two-step testing process to diagnose Lyme disease. This test detects antibodies which can take several weeks to develop in the body. If you are bitten by a tick, there is at least a 4 – 6 week waiting period before you can be tested for Lyme disease. Hopefully, your body will develop antibodies for testing. If it does not, the test may be negative even though you may be infected. There is a vital need for a diagnostic that does not rely on antibodies to detect disease.

You can help advance a Lyme disease diagnostic test with increased sensitivity and specificity than the standard serological tests available today.



  • Tests that rely on antibodies that your body makes in response to the infection
    delay time to diagnosis and treatment.
  • If you don’t get treated for Lyme disease early, the infection can spread to your
    joints, heart, nervous system, and other parts of the body. Making it difficult to
  • An EARLY Lyme disease diagnosis is important for a better treatment outcome and recovery.

About DiaSorin

This study is sponsored by DiaSorin, a global leader in the laboratory diagnostics market, specializing in the immunodiagnostics and molecular diagnostics segments. For over 50 years, they have been developing diagnostics to help physicians and patients make better decisions in the most important moments. GLA has partnered with DiaSorin to raise awareness of this important study.

For More Information

  • Learn more about clinical trial participation Click Here
  • Contact GLA for general information on tick bites and Lyme disease at Education@GLA.org
  • Contact your nearest enrolling center for information on study participation.

Enrolling Now. Get Started.

Please answer a few questions and submit to your preferred enrollment center. The center will be in touch to let you know if you've qualified.